$CLMT

Calumet (CLMT) Q2 2026 Earnings Call Transcript

Calumet (CLMT) reported Q2 2026 Adjusted EBITDA with Tax Attributes of $175.2 million, driven by Specialty Products and Solutions at $161.7 million. Net loss was $95.9 million, mainly from non-cash RINs expenses of $163.6 million. The company said it repaid $115 million of debt in July, including $100 million note redemption, and discussed SAF expansion and hedges.

Original reporting
Published Aug 14, 2026, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Calumet (CLMT) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CLMTBullishMed
01

Why it matters

Traders can update models for cash flow, leverage trajectory, and SAF run-rate ramp assumptions, while stress-testing downside from RIN volatility and turnaround execution risk.

02

Market read

The call combines balance-sheet progress (debt redemption and leverage ratio) with a detailed SAF capacity ramp plan, but also flags RINs mark-to-market as a major driver of reported net loss.

03

What to watch

The SAF ramp depends on reactor reconfiguration downtime and turnaround execution; any delay could push the EBITDA capture timeline and weaken the credibility of the 2027-2028 capacity targets.

Relevance 8/10Novelty 6/10Timing: post-call, same-day positioning around Q2 2026 earnings takeaways and SAF/debt updates

Background

This is Calumet’s Q2 2026 earnings call transcript, covering segment Adjusted EBITDA, leverage, and the Montana Renewables SAF expansion plan.

Company-level read

Ticker impact

$CLMTBullishMedium confidence
Context

Calumet reported Q2 2026 Adjusted EBITDA with tax attributes of $175.2M, plus debt reduction of $115M in July and SAF run-rate targets.

Expected impact

Moderate positive bias, with upside contingent on execution of the SAF reactor reconfiguration and continued cash flow to sustain debt paydown.

Evidence & confidence

Key disclosed datapoints include $90M cash flow from operations, $115M July debt reduction (including $100M note redemption), and a stated SAF run-rate ramp to 120-150M gallons by spring 2027 and 200M by 2028. Offsetting negatives include a large net loss driven by non-cash RINs mark-to-market and foregone margin during the MaXTA-150 turnaround.

Market effects

Highlights ongoing structural tightness in specialty products and base oil imbalances, which can influence refining and renewable fuels sentiment.

Montana Renewables execution and turnaround timing can affect regional renewable diesel and SAF supply expectations.

References Middle Eastern capacity outages and European production losses, reinforcing global base oil supply constraints that may support margins.

Counterpoint

Despite strong operating cash flow and debt paydown, the reported net loss is heavily driven by non-cash RINs mark-to-market, so equity risk may remain elevated if RIN economics deteriorate.

Key entities

  • Calumet, Inc.

    Reported Q2 2026 Adjusted EBITDA with tax attributes of $175.2M, $90M cash flow from operations, and $115M debt reduction in July, alongside SAF expansion targets.

  • Montana Renewables

    Discussed MaXTA-150 expansion turnaround impacts and MaxSAF 150 progress, including current SAF run rate and future capacity targets.

  • Specialty Products and Solutions segment

    Reported $161.7M Adjusted EBITDA driven by specialty product shortages and commercial execution, partially offset by LIFO headwinds in Performance Brands.

  • Performance Brands segment

    Reported $6.3M Adjusted EBITDA, citing a $7.3M LIFO inventory headwind from input cost spikes before pricing actions.

Related articles

$CLMTMed

Why Calumet Stock Is Rocketing Higher Today

Calumet (CLMT) shares rose 15.2% to about $5.99 by 2:36 p.m. ET after a 6.8% drop the prior week. Bank of America kept a buy rating and raised its price target to $45 from $38, citing stronger free cash flow and debt retirement. Calumet reported about $54M free cash flow in Q2 2026 and retired $115M debt in July.

$CLMTMedAI 8/10

CLMT Stock Jumps As Revenue Beats And Debt Falls

Calumet Inc (NASDAQ: CLMT) shares rose about 10.56% after Q2 results and guidance. The company reported Q2 revenue of $1.45B versus a FactSet estimate of $1.12B, with EPS improving to -$1.09 from -$1.70. Operating cash flow was about $92.3M and free cash flow about $54M, alongside $115M debt reduction in July. Goldman Sachs raised its CLMT price target to $40 from $36 but kept a Neutral rating.

$CLMTMed

CLMT Stock Jumps As Revenue Beat Fuels Deleveraging Story

Calumet Inc. (CLMT) shares rose about 10.56% after the company reported Q2 revenue of $1.45B versus $1.12B expected, and narrowed its EPS loss to -$1.09 from -$1.70. The quarter included $54M free cash flow and management cited $115M debt reduction in July, alongside a MaxSAF 150 expansion at Montana Renewables.

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.

$CLMTMed

Calumet (NASDAQ:CLMT) Surprises With Strong Q2 CY2026

Calumet (NASDAQ:CLMT) reported Q2 CY2026 results. Revenue rose 40.8% year on year to $1.45 billion, beating Wall Street estimates by 32% (according to the article). Adjusted EBITDA exceeded consensus by 78.2%, with margin rising to 12.1%. Free cash flow was $99.35 million, turning positive after a year-ago loss.